POTENTIAL DISEASE-MODIFYING EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR (AT1) ANTAGONISTS FOR THE TREATMENT OF PARKINSON DISEASE

UDOVIN, LUCAS DANIEL; OTERO-LOSADA, MATILDE; BORDET, SOFÍA; CHEVALIER GUENSON; QUARRACINO, CECILIA; CAPANI, FRANCISCO; PEREZ-LLORET, SANTIAGO

Congreso; V REUNIÓN CONJUNTA DE SOCIEDADES DE BIOLOGÍA DE LA REPÚBLICA ARGENTINA; 2020

Several studies in murine experimental models of Parkinson´s disease (PD) suggest neuroprotective properties for Angiotensin II AT1 receptor antagonists (ARAs) and Angiotensin Converting Enzyme inhibitors (ACEis). We explored the potential disease-modifying effects of these drugs in the Parkinson?s Progress Marker Initiative (PPMI) study database. The 423 treatment-naïve newly diagnosed PD patients from the PPMI were included in this study. In the first phase of this study, both the t and chi-square tests revealed no significant associations between exposure to ACEis and L-DOPA requirement (adjusted Odds Ratio, 95% confidence interval: 1,45, 0,58-3,59; p= 0,4). In the retrospective analysis of the first four years follow-up (the statistic used was the general estimation equations focused on changes averaged by subjects), MDS-UPDRS 2+3 scores in the ?practically-defined OFF-condition? was significantly lower in patients exposed to ARAs (0,88, 0,79?0,98; p=0,03) compared to unexposed patients. No associations were found with ACEis. Conclusions: These results show signals of a potential disease-modifying effect with ARAs in the PD. Further clinical trials are warranted.